公开(公告)号：EP4320114A1

公开(公告)日：2024-02-14

申请号：EP22720147.2

申请日：2022-04-07

申请人： CHDI Foundation, Inc.

发明人： LIU, Longbin ,  DOMINGUEZ, Celia ,  BARD, Jonathan ,  BROWN, Christopher John ,  CHEN, Xuemei ,  CLARK-FREW, Daniel ,  MILLS, Matthew Robert ,  JOHNSON, Peter David ,  GADOULEAU, Elise

IPC分类号： C07D401/14 ,  A61P25/00

公开(公告)号：EP4006016A2

公开(公告)日：2022-06-01

申请号：EP21192872.6

申请日：2015-08-28

申请人： CHDI Foundation, Inc.

发明人： DOMINGUEZ, Celia ,  WITYAK, John ,  BARD, Jonathan ,  KISELYOV, Alex ,  BROWN, Christopher John ,  GALAN, Sebastien Rene Gabriel ,  PRIME, Michael Edward ,  GILES, Paul Richard ,  GADOULEAU, Elise Lucienne Paulette ,  KRÜLLE, Thomas Martin ,  CLARK-FREW, Daniel ,  JOHNSON, Peter David ,  COE, Samuel ,  HAYES, Sarah

IPC分类号： C07D263/57 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D413/12 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

摘要： Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：EP2751086A1

公开(公告)日：2014-07-09

申请号：EP12827656.5

申请日：2012-08-28

申请人： CHDI Foundation, Inc.

发明人： COURTNEY, Stephen Martin ,  PRIME, Michael ,  MITCHELL, William ,  BROWN, Christopher John ,  DE AGUIAR PENA, Paula C. ,  JOHNSON, Peter ,  DOMINGUEZ, Celia ,  TOLEDO-SHERMAN, Leticia M. ,  MUNOZ, Ignacio

IPC分类号： C07D239/47

CPC分类号： C07D239/28 ,  A61K31/506 ,  C07D239/42 ,  C07D239/52 ,  C07D401/04 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/465

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：EP3186233A1

公开(公告)日：2017-07-05

申请号：EP15836321.8

申请日：2015-08-28

申请人： CHDI Foundation, Inc.

发明人： DOMINGUEZ, Celia ,  WITYAK, John ,  BARD, Jonathan ,  KISELYOV, Alex ,  BROWN, Christopher John ,  GALAN, Sebastien Rene Gabriel ,  PRIME, Michael Edward ,  GILES, Paul Richard ,  GADOULEAU, Elise Luciennen Paulette ,  KRÜLLE, Thomas Martin ,  CLARK-FREW, Daniel ,  JOHNSON, Peter David ,  COE, Samuel ,  HAYES, Sarah

IPC分类号： C07D279/00

CPC分类号： C07D513/04 ,  A61K51/0455 ,  A61K51/0459 ,  A61K51/0463 ,  C07D263/57 ,  C07D405/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

摘要： Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

摘要翻译： 提供包含式（I）化合物或其药学上可接受的盐的成像剂及其使用方法。

公开(公告)号：EP2750677B1

公开(公告)日：2017-03-22

申请号：EP12828501.2

申请日：2012-08-28

申请人： CHDI Foundation, Inc.

发明人： COURTNEY, Stephen Martin ,  PRIME, Michael ,  MITCHELL, William ,  BROWN, Christopher John ,  DE AGUIAR PENA, Paula C. ,  JOHNSON, Peter ,  DOMINGUEZ, Celia ,  TOLEDO-SHERMAN, Leticia M. ,  MUNOZ, Ignacio

IPC分类号： A61K31/44 ,  C07D403/04 ,  C07D405/14 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07H13/10

CPC分类号： C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：EP2750677A1

公开(公告)日：2014-07-09

申请号：EP12828501.2

申请日：2012-08-28

申请人： CHDI Foundation, Inc.

发明人： COURTNEY, Stephen Martin ,  PRIME, Michael ,  MITCHELL, William ,  BROWN, Christopher John ,  DE AGUIAR PENA, Paula C. ,  JOHNSON, Peter ,  DOMINGUEZ, Celia ,  TOLEDO-SHERMAN, Leticia M. ,  MUNOZ, Ignacio

IPC分类号： A61K31/44 ,  C07D401/00

CPC分类号： C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

摘要翻译： 本文提供了某些化学实体。 还提供了包含至少一种化学实体和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有对抑制KMO活性有响应的某些疾病和病症的患者的方法，其包括向这些患者施用有效量的至少一种化学实体，以减轻疾病或病症的体征或症状。 这些疾病包括神经退行性疾病，如亨廷顿病。 还描述了治疗方法，包括施用至少一种化学实体作为单一活性剂或施用与一种或多种其他治疗剂组合的至少一种化学实体。 还提供了筛选能够抑制KMO活性的化合物的方法。

公开(公告)号：EP4006016A3

公开(公告)日：2022-11-16

申请号：EP21192872.6

申请日：2015-08-28

申请人： CHDI Foundation, Inc.

发明人： DOMINGUEZ, Celia ,  WITYAK, John ,  BARD, Jonathan ,  KISELYOV, Alex ,  BROWN, Christopher John ,  GALAN, Sebastien Rene Gabriel ,  PRIME, Michael Edward ,  GILES, Paul Richard ,  GADOULEAU, Elise Lucienne Paulette ,  KRÜLLE, Thomas Martin ,  CLARK-FREW, Daniel ,  JOHNSON, Peter David ,  COE, Samuel ,  HAYES, Sarah

IPC分类号： C07D263/57 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D413/12 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

摘要： Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：EP3340796A1

公开(公告)日：2018-07-04

申请号：EP16842715.1

申请日：2016-08-26

申请人： CHDI Foundation, Inc.

发明人： DOMINGUEZ, Celia ,  WITYAK, John ,  BARD, Jonathan ,  BROWN, Christopher John ,  PRIME, Michael Edward ,  JOHNSON, Peter David ,  KRULLE, Thomas Martin ,  CLARK-FREW, Daniel ,  HIGGINS, Duane ,  MILLS, Matthew Robert ,  MARSTON, Richard Waldron ,  COE, Samuel ,  GREEN, Samantha Louise Jones ,  HAYES, Sarah

IPC分类号： A01N43/42

CPC分类号： A61K51/0455 ,  A61K51/0459 ,  C07B59/002 ,  C07D487/04 ,  C07D513/04 ,  C07D513/14

摘要： Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use. (I).

公开(公告)号：EP3243515A1

公开(公告)日：2017-11-15

申请号：EP17161699.8

申请日：2012-08-28

申请人： CHDI Foundation, Inc.

发明人： COURTNEY, Stephen Martin ,  PRIME, Michael ,  MITCHELL, William ,  BROWN, Christopher John ,  DE AGUIAR PENA, Paula C. ,  JOHNSON, Peter ,  DOMINGUEZ, Celia ,  TOLEDO-SHERMAN, Leticia M. ,  MUNOZ, Ignacio

IPC分类号： A61K31/44 ,  C07D403/04 ,  C07D405/14 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07H13/10

CPC分类号： C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：EP3186241A1

公开(公告)日：2017-07-05

申请号：EP15836970.2

申请日：2015-08-28

申请人： CHDI Foundation, Inc.

发明人： DOMINGUEZ, Celia ,  WITYAK, John ,  BARD, Jonathan ,  BROWN, Christopher John ,  KRÜLLE, Thomas Martin ,  CLARK-FREW, Daniel ,  HAYES, Sarah

IPC分类号： C07D403/02

摘要： Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

摘要翻译： 提供了包含式I化合物或其药学上可接受的盐的显像剂及其使用方法。